Skip to contentS
Surgery Partners, Inc.
S
SGRYSurgery Partners, Inc. Q3 2024 · 10-Q
Revenue$770.40M$770.40M+14.3% vs Q3 2023 Net Income-$31.70M-$31.70MN/M vs Q3 2023 EPS Diluted-$0.25-$0.25N/M vs Q3 2023 Operating Income$60,900,000−26.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Surgery Partners, Inc. · CIK 1638833 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$45,000,000−47.5% Margins · derivedOperating margin7.9%−4.3 pt vs Q3 2023
Net margin-4.1%−3.4 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end